To the Editor.—
According to Koranda et al,1 for patients receiving immunosuppressive therapy, the incidence of herpes simplex is 35% and the incidence of herpes zoster is 13%. It is further noted that skin complications in transplant patients range from minor annoyances to life-threatening conditions.It has been my good fortune to become acquainted with glutaraldehyde, a cold sterilant, which is better than 11 others used for that purpose.2 In reading the literature on this chemical, I was struck by the ability of 2% buffered glutaraldehyde to completely inhibit herpes simplex within ten minutes, in addition to its bactericidal, tuberculocidal, and pseudomonacidal effects.3I have reported a series of 12 patients with herpes simplex and four cases of herpes zoster very effectively treated, after informed consent, with 2% alkaline-buffered glutaraldehyde.4 Prior and subsequent experiences with this chemical have been favorable. As an analogue of formaldehyde,
Gordon HH. Glutaraldehyde in Treating Herpes Simplex and Herpes Zoster. Arch Dermatol. 1976;112(8):1178. doi:10.1001/archderm.1976.01630320076030
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: